Pharmacists in Frisco, Colorado


13 Pharmacists found in Frisco
female pharmacist

Allison Nicole Herbst, PHARMD


Pharmacist
1008 Summit Blvd, Frisco, CO 80443
970-668-9980    

female pharmacist

Amy Hurwitch, PHARMD


Pharmacist
340 Peak One Drive, Frisco, CO 80443
970-668-9588     970-668-6987

female pharmacist

Ashley Adams, PHARMD


Pharmacist
340 Peak One Dr, Frisco, CO 80443
404-803-3502    



female pharmacist

Charlotte Rorex


Pharmacist
840 Summit Blvd, Frisco, CO 80443
970-668-5961     970-668-3703

male pharmacist

David Bigelow, RPH


Pharmacist
1008 N Summit Blvd, Frisco, CO 80443
970-668-9980     970-668-9918

female pharmacist

Frances Rochelle Eisemann, PHARMD


Pharmacist
840 Summit Boulevard, Frisco, CO 80443
970-668-5961     970-668-3703

male pharmacist

Grant Padovich, PHARMD


Pharmacist
840 Summit Blvd, Frisco, CO 80443
970-668-5961    

female pharmacist

Miss Jacquelyn Goldberg, RPH


Pharmacist
29 Siskin Lane, Frisco, CO 80443
970-333-1500    

female pharmacist

Marcia Wessels, PHARMD


Pharmacist
340 Peak One Drive, Pharmacy, Frisco, CO 80443
970-668-6997     970-668-6987

female pharmacist

Dr. Nicole Moore, PHARMD


Pharmacist
1008 Summit Blvd, Frisco, CO 80443
970-668-9980     970-668-9918

female pharmacist

Rebecca Glotzbach, PHARM. D,


Pharmacist
340 Peak One Dr, Frisco, CO 80443
970-668-6997     970-668-6987

female pharmacist

Roselle Ciccone, PHARMD


Pharmacist
1008 Summit Blvd, Frisco, CO 80443
970-668-5144    

male pharmacist

Mr. Scott Gray, R.PH.


Pharmacist
1008 N. Summit Blvd., Frisco, CO 80443
970-668-9980     970-668-9918


Type of Pharmacists:
Psychiatric Pharmacist: A licensed pharmacist who has demonstrated specialized knowledge and skill in optimizing care of patients with psychiatric illness by assessing and monitoring patients, recognizing drug-induced problems, and recommending appropriate treatment plans.
Oncology Pharmacist: A licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases.